Form 4: Third Harmonic Bio Chief Scientific Officer Receives Stock Options and Restricted Stock Units

Third Harmonic Bio's Chief Scientific Officer, Christopher Dinsmore, was granted stock options and restricted stock units as part of the company's annual equity refresh.

Summary

• Christopher Dinsmore, the Chief Scientific Officer of Third Harmonic Bio, received stock options and restricted stock units.
• The stock options grant is for 116,000 shares with an exercise price of $6.
• These options vest over four years, with an initial 2.0833% vesting on February 15, 2025, and then 2.0833% monthly thereafter.
• Dinsmore also received 14,500 restricted stock units (RSUs), each representing one share of common stock.
• The RSUs vest over four years, with 1/4 vesting on February 15, 2026, and then 1/4 annually thereafter.
• The grants were approved by the board on December 17, 2024, with an effective date of January 15, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally positive for aligning management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options and RSUs aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.
• The equity grants are part of the company's annual refresh process, indicating a regular practice of incentivizing key personnel.

Risks

• The value of the stock options and RSUs is dependent on the future performance of the company's stock price.
• If the executive leaves the company before the vesting period is complete, they may forfeit unvested options and RSUs.

Future Outlook

The vesting schedules for the stock options and RSUs are designed to incentivize long-term performance and retention of the Chief Scientific Officer.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• Vesting schedules of four years with a mix of monthly and annual vesting are typical for these types of grants.
• Companies like Moderna, BioNTech, and Regeneron also use similar equity-based compensation to incentivize their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, executive compensation, insider trading, Form 4, THRD, Third Harmonic Bio